Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
주식 순위 #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
주가
$17.64
시가총액
$32.65B
변동 (1일)
-3.24%
변동 (1년)
-23.70%
국가
JP
거래 Daiichi Sankyo Company, Limited (DSNKY)

카테고리

Daiichi Sankyo Company, Limited (DSNKY)의 매출
Dec 2025 기준 매출 TTM: $13.20B
Daiichi Sankyo Company, Limited의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $13.20B입니다. 2024년에 회사는 $10.58B의 수익을 올렸으며 이는 2023년의 $9.63B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Daiichi Sankyo Company, Limited의 수익 기록 (2000 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $13.20B 4.91%
2025 $12.58B 18.91%
2024 $10.58B 9.90%
2023 $9.63B 12.20%
2022 $8.58B -1.25%
2021 $8.69B -4.84%
2020 $9.13B 9.03%
2019 $8.38B -7.32%
2018 $9.04B 5.39%
2017 $8.58B -2.19%
2016 $8.77B 14.38%
2015 $7.67B -29.30%
2014 $10.84B 2.39%
2013 $10.59B -6.41%
2012 $11.31B -3.05%
2011 $11.67B 14.54%
2010 $10.19B 19.06%
2009 $8.56B -3.04%
2008 $8.83B 12.02%
2007 $7.88B 0.11%
2006 $7.87B 43.33%
2005 $5.49B -4.11%
2004 $5.73B 18.80%
2003 $4.82B 16.37%
2002 $4.14B -4.69%
2001 $4.35B -24.27%
2000 $5.74B 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$65.18B 393.73%
US
$58.74B 344.95%
GB
$94.19B 613.52%
US
$61.16B 363.29%
US
$56.15B 325.33%
CH